Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Guide on how to report suspected Reactions Adverse directed to promoters of studies observational drugs for use Human, not Marketing Authorisation Holders

https://www.aemps.gob.es/investigacionClinica/medicamentos/docs/instrucciones-notificar-promotor-EPA-no-TAC2.pdf?x54046

Philippe Calandra 18 June 2021 All news
  • ← Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2021
  • Highlights of Management Board: June 2021 meeting →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024
  • European regulation on clinical trials for medicinal products: The end of the transition period
  • The ANSM publishes its haemovigilance report for 2023
Copyright © 2018 - Pharmya - Legal terms - Quality Policy